Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
Description: Alere Inc. provides point-of-care diagnostics and services for cardiology, infectious disease, toxicology, and diabetes in the United States and internationally. Its Professional Diagnostics segment provides diagnostic test products and other in vitro diagnostic tests to medical professionals and laboratories for detection of diseases and conditions in the areas of cardiology, infectious diseases, toxicology, diabetes, oncology, and women?s health, as well as offers connected device technologies. The company?s Health Information Solutions segment offers integrated programs and services focused on wellness, disease and condition management, productivity enhancement, and informatics. This segment?s health improvement programs comprise patient self-testing, condition and case management, women?s and children?s health, and health and wellness programs. Its Consumer Diagnostics segment provides products for over-the-counter pregnancy and fertility/ovulation test markets; and over-the-counter drug tests for at-home
|Shares Outstanding||EPS||-2.2||EPS Growth - 4 Quarters||-466.28%||EPS Growth - Q/Q||92.35%|
|EPS Growth - Y/Y||-37.2%||Sales Growth - 4 Quarters||-26.67%||Sales Growth - Q/Q||-8.8%||P/E||-22.82|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||2.88%||ROE||8.54%||ROI||3.38%|
|Current Ratio||2.18||Quick Ratio||1.61||Long Term Debt/Equity||3.9||Debt Ratio||0.32|
|Gross Margin||46.69%||Operating Margin||3.54%||Net Profit Margin||6.88%||Dividend Payout Ratio||-12.03%|
|Cash From Financing Activities||-566.72 M||Cash From Investing Activities||557.21 M||Cash From Operating Activities||28.38 M||Gross Profit||293.49 M|
|Net Profit||209.14 M||Operating Profit||27.4 M||Total Assets||6.15 B||Total Current Assets||1.44 B|
|Total Current Liabilities||661.24 M||Total Debt||3.13 B||Total Liabilities||4.08 B||Total Revenue||608.15 M|
|High 52 week||50.99||Low 52 week||34.83||Last close||50.99||Last change||0%|
|RSI||Average true range||3.64||Beta||0.76||Volume||455.09 K|
|Simple moving average 20 days||0.41%||Simple moving average 50 days||1.77%||Simple moving average 200 days||10.29%|
|Performance Week||0%||Performance Month||1.27%||Performance Quart||1.13%||Performance Half||3.98%|
|Performance Year||15.62%||Performance Year-to-date||30.84%||Volatility daily||0.94%||Volatility weekly||2.1%|
|Volatility monthly||4.31%||Volatility yearly||14.92%||Relative Volume||142.33%||Average Volume||1.51 M|
|New High||New Low|
2017-11-02 14:55:08 | Public health care company to layoff 182, close two South Florida offices
2017-10-19 14:23:00 | Abbott Laboratories Q3 2017 Earnings Conference Call Transcript ABT
2017-10-05 15:35:10 | Alere Inc. -- Moody's to withdraw Alere's ratings following debt redemption
2017-10-03 19:01:00 | Lifshitz & Miller LLP Announces Investigation of Alere Inc., Emergent BioSolutions, Inc., Frontier Communications Corporation, HSN, Inc., Insys Therapeutics Inc., LSB Industries, Inc. and Otonomy, Inc.
2017-10-02 16:45:08 | Abbott to Gain from Alere's Takeover Due for Oct 3 Closure
2017-10-02 16:36:49 | Abbott-Alere Deal Wins Conditional US Antitrust Approval
2017-10-02 08:01:32 | See what the IHS Markit Score report has to say about Alere Inc.
2017-10-02 07:00:00 | Alere Receives FDA Clearance for Alere™ i Influenza A & B 2 Rapid Molecular Test
2017-09-29 13:28:17 | Alere Reaches Settlement With SEC
2017-09-29 12:12:00 | Alere Announces the U.S. Department of Justice Closes Investigation
2017-09-29 10:31:10 | Abbott Labs' Torturous Deal Saga Isn't Over Yet
2017-09-29 09:26:00 | Abbott Acquisition of Alere Set to Close on October 3, 2017
2017-09-28 21:37:00 | Alere Announces Agreement in Principle to Settle with the U.S. Department of Justice
2017-09-28 16:45:40 | [$$] Alere Settles With SEC Over Accounting-Fraud Allegations
2017-09-28 15:04:00 | FTC Approves Abbott's Acquisition of Alere, Stock Jumps
2017-09-28 14:50:38 | Abbott wins U.S. antitrust approval to buy Alere with conditions
2017-09-28 14:20:11 | Waltham's Alere settles SEC accounting fraud charges for $13M
2017-09-28 12:42:59 | Alere to pay more than $13 million to resolve U.S. SEC probe
2017-09-28 11:50:00 | Alere Announces Settlement with SEC
2017-09-20 23:19:00 | Alere, Inc. – Value Analysis NYSE:ALR : September 21, 2017
2017-09-19 12:23:00 | Here's Why Quidel Corporation Stock Is Popping Today
2017-09-18 20:22:00 | Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock
2017-09-11 10:06:54 | See what the IHS Markit Score report has to say about Alere Inc.
2017-09-06 10:07:07 | See what the IHS Markit Score report has to say about Alere Inc.
2017-09-04 08:01:56 | See what the IHS Markit Score report has to say about Alere Inc.
2017-09-01 08:04:50 | See what the IHS Markit Score report has to say about Alere Inc.
2017-08-31 08:10:16 | See what the IHS Markit Score report has to say about Alere Inc.
2017-08-30 08:05:10 | See what the IHS Markit Score report has to say about Alere Inc.
2017-08-28 08:11:12 | New Strong Sell Stocks for August 28th
2017-08-25 15:43:09 | ETFs with exposure to Alere, Inc. : August 25, 2017
2017-08-16 10:31:27 | Alere, Inc. :ALR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
2017-08-16 08:02:43 | See what the IHS Markit Score report has to say about Alere Inc.
2017-08-15 08:02:59 | See what the IHS Markit Score report has to say about Alere Inc.
2017-08-12 08:02:54 | See what the IHS Markit Score report has to say about DST Systems Inc.
2017-08-11 07:00:00 | Alere Provides Notice to Holders of Series B Convertible Perpetual Preferred Stock
2017-08-03 06:41:00 | Alere Reports Second Quarter 2017 Financial Results
2017-07-31 07:00:00 | Immunalysis Receives FDA Clearance for SEFRIA™ Fentanyl Urine Drug Screening Test
2017-07-25 14:06:05 | What Were Abbott’s Key Growth Drivers for 2Q17?
2017-07-24 15:25:10 | Abbott deal will cost Alere three business units — and untold employees
2017-07-20 12:00:00 | Abbott CEO: Another Alere-Related Divestiture Coming Soon
2017-07-19 15:56:00 | Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings
2017-07-18 17:21:00 | Quidel Diversifies With Alere's Triage Assets